{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:37:50Z","timestamp":1769236670692,"version":"3.49.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Selective estrogen receptor modulators (SERMs) exhibit a pharmacologic profile characterized by estrogen agonist activity in some tissues with estrogen antagonist activity in other tissues. These compounds were initially called \u201cantiestrogens,\u201d but it was subsequently recognized that this inadequately described their spectrum of activities. The first widely used SERM, tamoxifen, has estrogen antagonist activity in breast tissue but shows estrogen-like activity in other tissues. Raloxifene is another SERM in clinical use, and it was developed to avoid some of the undesirable estrogen agonist actions of other SERMs to improve the drug safety profile. Raloxifene has been introduced for clinical use in treatment and prevention of postmenopausal osteoporosis. This review will explore the preclinical and clinical pharmacology of raloxifene, and compare it to other SERMs currently available for clinical use.<\/jats:p>","DOI":"10.1634\/theoncologist.5-5-388","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"388-392","source":"Crossref","is-referenced-by-count":111,"title":["Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects"],"prefix":"10.1093","volume":"5","author":[{"given":"Douglas B.","family":"Muchmore","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,10,1]]},"reference":[{"key":"2021122209571406600_R1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122209571406600_R2","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jnci\/90.19.1461","article-title":"Biologic activity of tamoxifen at low doses in healthy women","volume":"90","author":"Decensi","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2021122209571406600_R3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/gyno.1995.0019","article-title":"Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients","volume":"59","author":"Tomas","year":"1995","journal-title":"Gynecol Oncol"},{"key":"2021122209571406600_R4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2021122209571406600_R5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"2021122209571406600_R6","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.273.5279.1222","article-title":"Identification of an estrogen response element activated by 17beta-estradiol and raloxifene","volume":"273","author":"Yang","year":"1996","journal-title":"Science"},{"key":"2021122209571406600_R7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2021122209571406600_R8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/jcem.83.4.4688","article-title":"Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients","volume":"83","author":"Marttunen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209571406600_R9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1089\/jwh.1998.7.839","article-title":"Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene","volume":"7","author":"Barrett-Connor","year":"1998","journal-title":"J Womens Health"},{"key":"2021122209571406600_R10","first-page":"146","article-title":"Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator","volume":"280","author":"Kauffman","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122209571406600_R11","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","article-title":"Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women","volume":"279","author":"Walsh","year":"1998","journal-title":"JAMA"},{"key":"2021122209571406600_R12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/82.16.1327","article-title":"Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer","volume":"82","author":"Love","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2021122209571406600_R13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1200\/JCO.1996.14.2.429","article-title":"Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer","volume":"14","author":"Saarto","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122209571406600_R14","first-page":"1","article-title":"Effects of raloxifene and hormone replacement therapy on homocysteine and C-reactive protein levels in postmenopausal women","volume":"98:","author":"Paul","year":"1998","journal-title":"Circulation"},{"key":"2021122209571406600_R15","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/jnci\/89.11.776","article-title":"Coronary heart disease mortality and adjuvant tamoxifen therapy","volume":"89","author":"Costantino","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2021122209571406600_R16","doi-asserted-by":"crossref","first-page":"152a","DOI":"10.1016\/1071-5576(96)82635-9","article-title":"Selective estrogen receptor modulators: pharmacological profile in the rat uterus","volume":"3","author":"Bryant","year":"1996","journal-title":"J Soc Gynecol Invest"},{"key":"2021122209571406600_R17","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"2021122209571406600_R18","first-page":"104","article-title":"Uterine effects of three-year raloxifene therapy in postmenopausal women younger than age 60","volume":"95","author":"Cohen","year":"2000","journal-title":"Obstet Gynecol"},{"key":"2021122209571406600_R19","first-page":"95","article-title":"A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium","volume":"95","author":"Goldstein","year":"2000","journal-title":"Obstet Gynecol"},{"key":"2021122209571406600_R20","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/BF02383389","article-title":"Raloxifene: a selective estrogen receptor modulator","volume":"12","author":"Sato","year":"1994","journal-title":"J Bone Miner Metab"},{"key":"2021122209571406600_R21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"2021122209571406600_R22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"key":"2021122209571406600_R23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"key":"2021122209571406600_R24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jnci\/92.1.48","article-title":"Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors","volume":"92","author":"Radmacher","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122209571406600_R25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"2021122209571406600_R26","first-page":"68","volume-title":"IV European Congress on Menopause Abstract Book, 8-12 October 1997","author":"Davies","year":"1999"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.5-5-388","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.5-5-388","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/5\/388\/41837128\/oncolo_5_5_388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/5\/388\/41837128\/oncolo_5_5_388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:56:53Z","timestamp":1640195813000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/5\/5\/388\/6386072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10,1]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2000,10,1]]},"published-print":{"date-parts":[[2000,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.5-5-388","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,10,1]]},"published":{"date-parts":[[2000,10,1]]}}}